Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Many advanced economies remain ill-prepared for present challenges28.5.2025 11:00:00 CEST | Press release
A shifting geopolitical landscape, sluggish growth, digital transformation, the climate crisis and demographic change are testing the capacity of OECD and EU countries to innovate and adapt like never before. Denmark, Finland, Sweden and Norway are among the best positioned. But the analysis of 144 indicators from the Bertelsmann Stiftung's Sustainable Governance Indicators (SGI) reveals a troubling pattern: most advanced economies are still not adequately equipped to deliver sustainable policy.
LONGi Green Energy Technology: World-leading solar tech available for private homes - Longi brings high-efficiency module series EcoLife to homeowners26.5.2025 14:49:29 CEST | Press release
Frankfurt am Main – Longi, one of the world’s leading solar manufacturers, is now bringing its most powerful residential module series EcoLife to the homeowner market. The most powerful version has an output of 510 watts and a surface area of just over two square meters, resulting in a power density of approximately 250 watts per square meter. The average wattage per square meter across all solar modules on the market today is approximately 220. This EcoLife module is currently the most efficient residential solar module worldwide according to recent rankings, with an efficiency exceeding 25 percent, well above the 21–24 percent range of standard modules. In solar, even a 1 percent gain represents a significant leap, especially for homes with limited roof space and a need for high energy yield.
Europe’s Largest Inaugural Tech and Startup Event Opens in Berlin as the Continent Spurs Momentum for Open Innovation and AI Leadership22.5.2025 08:24:50 CEST | Press release
Ministers and senior tech stakeholders from the European Union, Germany and the UAE inaugurate the momentous first edition of GITEX EUROPE x Ai Everything
Deutsche Rück Group maintains profit-oriented growth course21.5.2025 11:00:00 CEST | Press release
Düsseldorf, 21 May 2025 – The Deutsche Rück Group further expanded its business in the 2024 financial year while simultaneously strengthening its financial position. Gross premiums written grew in all business areas, rising significantly by 18.3% to around €2.1 billion. Net premiums earned increased by 17.5% to €1.4 billion. Growth came from both international markets and the German domestic market. Total security resources rose by €375.8 million to more than €3.1 billion.
Bertelsmann Stiftung: New white paper: Public AI as a democratic alternative to the concentration of private power20.5.2025 12:00:00 CEST | Press release
Gütersloh, May 20, 2025 The most powerful AI systems of our time were developed and are controlled by a small number of private companies – including OpenAI, Anthropic, Google DeepMind, Meta, and DeepSeek. These companies don’t just dominate the development of models, they control the basic infrastructure of the AI ecosystem: computing capacities, training data, and cloud services. This concentration of power is not just a technological reality – it is a political challenge. It raises a central question: Who designs the systems that are increasingly influencing our society?
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom